The evolving landscape of amyloid-targeting therapies in Alzheimer's disease: progress and challenges - PubMed
5 hours ago
- #Alzheimer's disease
- #Disease modification
- #Amyloid-targeting therapies
- Alzheimer's disease (AD) is the leading cause of dementia worldwide.
- Amyloid-β (Aβ) accumulation has guided therapeutic development, but early inhibitors failed to show clinical benefits.
- Monoclonal antibodies like aducanumab, lecanemab, and donanemab show significant amyloid clearance and modest cognitive decline slowing in Phase 3 trials.
- Clinical benefits of amyloid-targeting therapies are limited, with safety concerns like amyloid-related imaging abnormalities (ARIA) and high costs.
- The multifactorial pathology of AD, including tau, neuroinflammation, and vascular dysfunction, presents persistent therapeutic gaps.
- Amyloid-targeting therapies are the first validated disease-modifying strategy for AD but are not definitive solutions.
- Future directions include earlier intervention, combination therapies, improved antibody design, and scalable biomarker implementation.